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Introduction 
We have a problem. Many microbial pathogens are becoming resistant to conventional 
therapeutics, and are no longer affected by them. We need to develop the next generation of 
antimicrobials or return to times when a minor bacterial infection could be fatal. Antimicrobial 
peptides (AMPs) typically have broad-spectrum specificity, which makes them ideal for critical 
treatment situations when the identity of the pathogen is unknown. Pleurocidin, an AMP found 
in secretions from winter flounder (Pleuronectes americanus), adopts an amphipathic -helical 
structure crucial for activity, and this conformation is induced or stabilized by peptide-
membrane interactions [1]. We evaluated the impacts of novel pleurocidin analogs on the 
exponential growth curves of two Gram (+) and two Gram (-) human pathogens using high-
throughput broth bioassays capable of simultaneous monitoring the growth of multiple bacterial 
species on a single 96-well plate [2]. Our hypothesis holds that specific additions to the 
N-terminus of our “base peptide” pleurocidin-amide, (LM4-12), which were designed to 
enhance initiation of peptide-cell membrane interactions, will increase antimicrobial efficacy 
and selectivity [3]. We have tested the effects of grafting combinations of R, G, & W onto the 
N-terminus of base peptide LM4-12, synthesized using Boc-SPPS methods on an MBHA resin 
[4]. Comparison of the effects of adding each of these three amino acids to the N-terminus of 
LM4-12 generated the lead peptide LM4-15, with an N-terminal arginine, that yielded 
dramatically improved broad-spectrum efficacy against Enterococcus faecalis (EF), 
Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA) and Escherichia coli (EC). 
 
LM4-15 (N-Ter) H-RGWGSFFKKAAHVGKHVGKAALTHYL-NH2 (C-Ter) 
Fig. 1. Lead Peptide LM4-15. 
Results and Discussion 
Lead peptide LM4-15 (Figure 1) showed a significant efficacy against all four human 
pathogens, with 48% growth inhibition relative to untreated bacterial cultures at the maximum 
tested dose (25 µg/mL, 8.72 µM). Base peptide LM4-12 (Figure 2) showed a similar inhibitory 
effect, but only on two of the four pathogens (both Gram +), and some species selectivity, with 
the highest efficacy against SA. Growth inhibition was calculated as the OD630 of peptide-
treated bacteria, divided by the OD630 of identical untreated cells grown in broth cultures, under 
the same conditions, measured 20 hours after a single treatment with the test peptide at the 
indicated dose.   











Fig. 2. Base Peptide LM4-12. 
MIC assays typically test the effectiveness of potential antibiotics using a fairly low (104 
CFU) inoculum of bacteria.  Our data, obtained at a higher starting concentration of bacteria 
(OD630 = 0.12 at t = 0), shows that LM4-12 reached a maximum efficacy for SA, and EC at the 
second highest dose of the base peptide tested (5.5 µg/mL, 1.85 µM), but was not effective 
against either PA or EF, even at the highest tested dose (23.5 µg/mL, 8.64 µM).  LM4-15 
however, was found to reach a much higher efficacy against all 4 target species at the maximum 
tested dose of the lead peptide (25.0 µg/mL, 8.72 µM), attaining an efficacy of greater than 48% 
growth inhibition when tested on gram positive microorganisms SA and EF.  What is more, 
LM4-15, at the highest tested dose, showed greater than 73% growth inhibition when tested on 
the gram negatives, EC and PA, which were not inhibited by LM4-12 to any great extent 
(Figures 3-6). 
 Fig. 3. EF (G+).           Fig. 4.PA (G-).               Fig. 5. EC (G-).              Fig. 6. SA (G+). 
 
In conclusion, modifying the N-terminus of the base antimicrobial peptide by adding 
arginine dramatically enhanced antimicrobial efficacy in the lead peptide LM4-15 over that of 
the base peptide LM4-12.  As the assay data in Figures 1 and 2 demonstrates, peptide doses as 
low as 5 µg/mL slightly retard bacterial growth, with a significant level of inhibition reached at 
only 25 µg/mL, the maximum dose assayed in these experiments.  Comparing the efficacies of 
the lead and base peptides with those of a known antibiotic, oligomycin, confirmed that the lead 
peptide inhibited bacterial growth of three of the four pathogenic microbial species tested (EF, 
PA, and EC) as well as (or better than) the known antibiotic in our assays.  This lead peptide 
shows great promise as a therapeutic agent, especially now that more bacteria are becoming 
increasingly resistant to conventional antibiotics.  The dramatic increase in antibiotic efficacy 
observed with a single arginine addition onto the N-terminus of pleurocidin in LM4-15, versus 
the low efficacy of similar synthetic peptide analogs prepared with tryptophan, lysine, and 
glycine at that position, suggests that N-terminal arginine addition onto existing AMPs may 
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